Intelgenx Technologies (Intelgenx Technologies) Debt-to-Equity

: -1.27 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Intelgenx Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.40 Mil. Intelgenx Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.11 Mil. Intelgenx Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-12.25 Mil. Intelgenx Technologies's debt to equity for the quarter that ended in Dec. 2023 was -1.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intelgenx Technologies's Debt-to-Equity or its related term are showing as below:

IGXT' s Debt-to-Equity Range Over the Past 10 Years
Min: -10.41 Med: 0.66 Max: 29.99
Current: -1.27

During the past 13 years, the highest Debt-to-Equity Ratio of Intelgenx Technologies was 29.99. The lowest was -10.41. And the median was 0.66.

IGXT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs IGXT: -1.27

Intelgenx Technologies Debt-to-Equity Historical Data

The historical data trend for Intelgenx Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

29.99

-10.41

2.96

-3.07

-1.27

Intelgenx Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																-3.07	-2.24	-1.55	-1.42	-1.27

Competitive Comparison

For the Biotechnology subindustry, Intelgenx Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelgenx Technologies Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's Debt-to-Equity falls into.

Intelgenx Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intelgenx Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.395	+	12.106)	/	-12.247
	=	-1.27

Intelgenx Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.395	+	12.106)	/	-12.247
	=	-1.27

Intelgenx Technologies (OTCPK:IGXT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Intelgenx Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelgenx Technologies (Intelgenx Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0IL:Germany IGX:Canada

Address

6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2

Website

https://www.intelgenx.com

Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.

Executives

Atai Life Sciences Ag	10 percent owner	KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v.	10 percent owner	524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian	officer: VP, Finance&Admin - Subsidiary	4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham	officer: CEO	15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel	officer: SVP, Corp. Dev&SA - Subsidiary	23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe	10 percent owner, officer: Chief Executive Officer	714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin	officer: CFO	440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny	officer: VP IP,Lgl Affairs - Subsidiary	88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen	officer: VP Business+Corp. Development	4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe	10 percent owner, officer: Corporate Secretary	714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid	officer: Vice President, Operations	4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau	director	2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham	officer: Vice President Manufacturing	102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki	director	118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard	officer: VP Corporate Development	141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4